Does activation of the protective Renin-Angiotensin System have therapeutic potential in COVID-19?

Area of Science:

• Cardiovascular Science
• Infectious Disease
• Pulmonary Medicine

Background:

• Coronavirus infection disrupts the balance of angiotensin II signaling pathways in lung cells.
• This imbalance, characterized by overstimulation of the angiotensin II type 1 receptor, contributes to inflammation, edema, and severe acute respiratory distress syndrome (ARDS).

Purpose of the Study:

• To propose that stable, receptor-specific agonists targeting the angiotensin II type 2 receptor and Mas receptor can serve as molecular medicines for COVID-19.
• To explore the therapeutic potential of these agonists in managing acute COVID-19 and mitigating long-term pulmonary dysfunction and end-organ damage.

Main Methods:

• This study is a hypothesis-driven research paper.
• It focuses on the proposed therapeutic mechanisms of angiotensin II receptor agonists in the context of COVID-19 pathogenesis.

Main Results:

• The hypothesis posits that restoring balance in the renin-angiotensin system through specific receptor agonists can counteract COVID-19-induced lung injury.
• Unbalanced angiotensin II type 1 receptor stimulation is implicated in the pathogenesis of severe COVID-19.

Conclusions:

• Stable agonists for angiotensin II type 2 receptor and Mas receptor represent a potential therapeutic strategy for COVID-19.
• These agonists may offer benefits for both acute disease management and the reduction of long-term sequelae associated with COVID-19.